{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:40:02Z","timestamp":1786560002997,"version":"build-2736575974"},"reference-count":159,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["SNF 31003 A_175458"],"award-info":[{"award-number":["SNF 31003 A_175458"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prevalence of obesity and associated comorbidities such as type 2 diabetes and cardiovascular disease is increasing globally. Body\u2010weight loss reduces the risk of morbidity and mortality in obese individuals, and thus, pharmacotherapies that induce weight loss can be of great value in improving the health and well\u2010being of people living with obesity. Treatment with amylin and calcitonin receptor agonists reduces food intake and induces weight loss in several animal models, and a number of companies have started clinical testing for peptide analogues in the treatment of obesity and\/or type 2 diabetes. Studies predominantly performed in rodent models show that amylin and the dual amylin\/calcitonin receptor agonist salmon calcitonin achieve their metabolic effects by engaging areas in the brain associated with regulating homeostatic energy balance. In particular, signalling via neuronal circuits in the caudal hindbrain and the hypothalamus is implicated in mediating effects on food intake and energy expenditure. We review the current literature investigating the interaction of amylin\/calcitonin receptor agonists with neurocircuits that induce the observed metabolic effects. Moreover, the status of drug development of amylin and calcitonin receptor agonists for the treatment of metabolic diseases is summarized.<\/jats:p>","DOI":"10.1111\/bcpt.13427","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T07:12:09Z","timestamp":1588576329000},"page":"163-177","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases"],"prefix":"10.1111","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4792-3948","authenticated-orcid":false,"given":"Hannah Louise","family":"Zakariassen","sequence":"first","affiliation":[{"name":"Section of Experimental Animal Models Department of Veterinary and Animal Science Faculty of Health and Medical Sciences University of Copenhagen Frederiksberg C Denmark"},{"name":"Obesity Pharmacology Novo Nordisk A\/S M\u00e5l\u00f8v Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linu Mary","family":"John","sequence":"additional","affiliation":[{"name":"Obesity Pharmacology Novo Nordisk A\/S M\u00e5l\u00f8v Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Alexander","family":"Lutz","sequence":"additional","affiliation":[{"name":"Institute of Veterinary Physiology University of Zurich Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00240-9"},{"key":"e_1_2_9_3_1","unstructured":"World Health Organization.Global health observatory (GHO) data \u2010 overweight and obesity.2018[updated 2018; cited 2018 18 Oct];http:\/\/www.who.int\/gho\/ncd\/risk_factors\/overweight_obesity\/obesity_adults\/en\/"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1514009"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2013.07.009"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.02.023"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2007.11.063"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2008.01104.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2008.08.005"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00047.2007"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.010629"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14075"},{"key":"#cr-split#-e_1_2_9_13_1.1","unstructured":"PR Newswire.Lilly announces strategic collaboration with keybioscience AG.2017[updated 2017"},{"key":"#cr-split#-e_1_2_9_13_1.2","unstructured":"cited 2018 31 dec];https:\/\/www.prnewswire.com\/news\u2010releases\/lilly\u2010announces\u2010strategic\u2010collaboration\u2010with\u2010keybioscience\u2010ag\u2010300470564.html"},{"key":"e_1_2_9_14_1","unstructured":"Novo Nordisk A\/S.Investor presentation full year 2016.2017[updated 2017; cited 2018 31 Dec];https:\/\/www.novonordisk.com\/content\/dam\/Denmark\/HQ\/investors\/irmaterial\/investor_presentations\/2017\/20170202_Q4%20Roadshow%20presentation.pdf"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00198.2011"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2010.02.023"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-0898"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.11.010"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2009.238"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0393"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000084488"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00297.2007"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01425.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00121.2014"},{"key":"e_1_2_9_25_1","first-page":"117","article-title":"Calcitonin and calcitonin receptors","volume":"4","author":"Masi L","year":"2007","journal-title":"Clin Cases Miner Bone Metab."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.008615"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(89)90407-2"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(89)81260-8"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)77825-9"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.1.141"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114528"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(89)81527-3"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00242.2009"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.39.6.752"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2006.04.001"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2011.04.044"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(92)90080-T"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978923"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(95)02067-5"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2004.01.006"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801664"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(94)90076-0"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2133"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1996.271.6.R1654"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(96)00168-2"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(97)90170-0"},{"key":"e_1_2_9_47_1","first-page":"524","article-title":"Roles of amylin in diabetes and in regulation of nutrient load","volume":"14","author":"Young A","year":"1998","journal-title":"Nutrition"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.280.3.E443"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050646"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401833"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00597.2001"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(99)00208-9"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(82)90010-9"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0031-6989(85)90095-5"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.90327.2008"},{"key":"e_1_2_9_56_1","first-page":"61","article-title":"Amylin receptor phenotypes derived from human calcitonin receptor\/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment","volume":"294","author":"Tilakaratne N","year":"2000","journal-title":"J Pharmacol Exp Ther."},{"key":"e_1_2_9_57_1","first-page":"493","article-title":"High affinity amylin binding sites in rat brain","volume":"44","author":"Beaumont K","year":"1993","journal-title":"Mol Pharmacol."},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.1.235"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2007.02.012"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/08977190410001728033"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-005-0613-8"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-144-37517"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M"},{"key":"e_1_2_9_64_1","first-page":"190","article-title":"In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin","volume":"297","author":"Chaturvedula A","year":"2005","journal-title":"Int J Pharm."},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2001.280.3.R605"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2002.018671"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.91"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2010.04.012"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0692"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-2172"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2008.02.002"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0849"},{"key":"e_1_2_9_73_1","volume-title":"Dual Amylin and Calcitonin Receptor Agonists: A Novel Treatment for Obesity and Related Co\u2010Morbidities","author":"Gydesen S","year":"2017"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.54.2.233"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1658"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01717.x"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.135.1.183"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1660213"},{"key":"e_1_2_9_79_1","first-page":"2269","article-title":"Calcitonin induction of a persistent activated state of adenylate cyclase in human breast cancer cells (T 47D)","volume":"256","author":"Lamp SJ","year":"1981","journal-title":"J Biol Chem."},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2018.11.005"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2017.12.016"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107987"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.9b00089"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1735"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00333.2003"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2010.03.114"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12596"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.13163"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-03259"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00380.2011"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2001.281.6.R1833"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.10.012"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2003.10.040"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(95)00322-A"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2004.10.012"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0953-816x.2001.01688.x"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(99)00335-6"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2017.03.023"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.2337\/db17-1347"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1994.267.1.R178"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(94)00203-I"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1998.274.6.R1777"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.12672"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-9384(98)00110-3"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(02)00280-2"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(97)00292-1"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00791.2009"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2007.06.016"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2018.03.007"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.12.012"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2015.01.003"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3211"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1455"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.02.004"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4495"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.02.007"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3149"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(03)00190-3"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0645"},{"key":"e_1_2_9_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/1082"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.036"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-0770"},{"key":"e_1_2_9_123_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0546"},{"key":"e_1_2_9_124_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706473105"},{"key":"e_1_2_9_125_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00179.2018"},{"key":"e_1_2_9_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2011.12.022"},{"key":"e_1_2_9_127_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00326.2015"},{"key":"e_1_2_9_128_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2001.281.5.R1442"},{"key":"e_1_2_9_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(02)00288-7"},{"key":"e_1_2_9_130_1","doi-asserted-by":"publisher","DOI":"10.1159\/000443093"},{"key":"e_1_2_9_131_1","doi-asserted-by":"publisher","DOI":"10.1159\/000363041"},{"key":"e_1_2_9_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06422.x"},{"key":"e_1_2_9_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3745"},{"key":"e_1_2_9_134_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00049"},{"key":"e_1_2_9_135_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2001.280.6.R1697"},{"key":"e_1_2_9_136_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.66"},{"key":"e_1_2_9_137_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.180"},{"key":"e_1_2_9_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.153"},{"key":"e_1_2_9_139_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1212137110"},{"key":"e_1_2_9_140_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.581663"},{"key":"e_1_2_9_141_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01465.x"},{"key":"e_1_2_9_142_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0210-109"},{"key":"e_1_2_9_143_1","unstructured":"Scrip Informa Pharma Intelligence.Takeda and amylin take obesity combo forward as davalintide dropped.2010[updated 2010; cited 2020 17 Mar];https:\/\/scrip.pharmaintelligence.informa.com\/SC007028\/Takeda\u2010and\u2010Amylin\u2010take\u2010obesity\u2010combo\u2010forward\u2010as\u2010davalintide\u2010dropped"},{"key":"e_1_2_9_144_1","unstructured":"Adis Insight.Dacra 089.2019[updated 2019; cited 2019 13 May];https:\/\/adisinsight.springer.com\/drugs\/800052601"},{"key":"e_1_2_9_145_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21563"},{"key":"e_1_2_9_146_1","unstructured":"KeyBioscience AG.Study to evaluate the efficacy and safety of KBP\u2010042 in patients with type 2 diabetes.2017[updated 2017; cited 2020 17 Mar];https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03230786?term=keybioscience"},{"key":"e_1_2_9_147_1","unstructured":"FierceBiotech.com.Lilly cuts a trio of pipeline assets including btk inhibitor diabetes drug.2019[updated 2019; cited 2019 16 Nov];https:\/\/www.fiercebiotech.com\/biotech\/lilly\u2010cuts\u2010a\u2010trio\u2010pipeline\u2010assets\u2010including\u2010btk\u2010inhibitor\u2010diabetes\u2010med"},{"key":"e_1_2_9_148_1","unstructured":"Medwatch.Danish biotech boss after shelved lilly project: \"We have better molecules\".2019[updated 2019; cited 2020 17 Mar];https:\/\/medwatch.dk\/secure\/Top_picks_in_english\/article11178874.ece"},{"key":"e_1_2_9_149_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13723"},{"key":"e_1_2_9_150_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00419.2016"},{"key":"e_1_2_9_151_1","unstructured":"Eli Lilly and Company.A clinical study to evaluate the safety tolerability PK PD and efficacy of KBP\u2010089 in patients with T2DM.2019[updated 2019; cited 2019 16 Nov];https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03907202?term=KBP\u2010089&draw=2&rank=1"},{"key":"e_1_2_9_152_1","unstructured":"Novo Nordisk A\/S.A research study of how NNC0174\u20100833 behaves in Japanese and Caucasian volunteers who are normal weight overweight or with obesity.2018[updated 2018; cited 2019 16 Nov];https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03787225?term=AM833&draw=2&rank=1"},{"key":"e_1_2_9_153_1","unstructured":"Novo Nordisk A\/S.Research study investigating how well NNC0174\u20100833 works in people suffering from overweight or obesity.2019[updated 2019; cited 2019 6 Dec];https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03856047?term=NN9838&draw=2&rank=2"},{"key":"e_1_2_9_154_1","unstructured":"Novo Nordisk A\/S.A research study of how nnc0174\u20100833 taken with semaglutide works in people who are overweight or obese.2018[updated 2018; cited 2019 16 Nov];https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03600480?term=AM833&draw=2&rank=2"},{"key":"e_1_2_9_155_1","unstructured":"Zealand Pharma A\/S.Long\u2010acting amylin analog (obesity\/diabetes).2019[updated 2019; cited 2019 06 Dec];https:\/\/www.zealandpharma.com\/longacting\u2010amylin\u2010analog"},{"key":"e_1_2_9_156_1","unstructured":"SkarbalieneJ JustR.Anti\u2010diabetic effects of novel long\u2010acting amylin analogues ZP4982 and ZP5461 in ZDF rats.2016[updated 2016; cited 2020 17 Mar];https:\/\/static1.squarespace.com\/static\/58983777d1758e28995640b4\/t\/5d4953643b48f80001ed9c5a\/1565086566205\/Jolanta+Skarbaliene+ADA+poster+Anti\u2010diabetic+effects+of+novel+long\u2010acting+amylin+analogues.pdf"},{"key":"e_1_2_9_157_1","unstructured":"SkarbalieneJ PaglerT EickelmannP JustR.Anti\u2010obesity effects of the novel long\u2010acting amylin analogue zp4982 in high\u2010fat diet fed rats2017[updated 2017; cited 2020 17 Mar];https:\/\/static1.squarespace.com\/static\/58983777d1758e28995640b4\/t\/5d4953761475550001d57ffe\/1565086584540\/Keystone+meeting+Copenhagen+2017+JSK+final.pdf"},{"key":"e_1_2_9_158_1","unstructured":"Boehringer Ingelheim.Evaluation of safety and tolerability of single rising doses of bi 473494 in healthy subjects.2017[updated 2017; cited 2020 24 Mar];https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03195088"},{"key":"e_1_2_9_159_1","unstructured":"GlobeNewswire.Zealand pharma regains worldwide rights to amylin analog program from boehringer ingelheim.2020[updated 2020; cited 2020 24 Mar];http:\/\/www.globenewswire.com\/news\u2010release\/2020\/03\/20\/2004337\/0\/en\/Zealand\u2010Pharma\u2010regains\u2010worldwide\u2010rights\u2010to\u2010Amylin\u2010analog\u2010program\u2010from\u2010Boehringer\u2010Ingelheim.html"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13427","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.13427","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T17:18:05Z","timestamp":1693934285000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":159,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/bcpt.13427"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13427","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,18]]},"assertion":[{"value":"2020-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}